“…The present study has shown that activation of GDNF/RET/AKT signaling inhibits the GSK3β activity and subsequently induces the proteolytic formation of GLI activators including GLI2-A and GLI3-F, resulting in increases in GLI activators and activation of HH signaling, thereby promotes the proliferation of NB cells and tumor growth. Our findings not only correspond to previous findings demonstrating that the synergy between PI3K/AKT and HH signaling occurs in embryonic development and HHdependent tumors, and that Igf2-AKT stabilizes full-length Gli2 through Serine 230 and in turn enhances the output of transcriptional activation by HH, but also correspond to previous observations indicating that AKT inhibits GSK3β activity in a variety of signaling pathways, such as Wnt, insulin, SHH, and mTOR pathways [35][36][37][38][39]. Since AKT is able to activate mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) and in turn promotes GSK3β-independent increases in GLI transcriptional activity and GDNF promotes mitogenic effect in SH-SY5Y cells through AKT and S6K1 signaling [40,41], in the present study, we are still unable to exclude the possibility that GDNF/RET/AKT activates HH signaling through mTOR/S6K1 pathway.…”